Abbott pays $170 million for PanGenetics' anti-NGF antibody
This article was originally published in Scrip
Abbott will pay $170 million up front to acquire a Phase I nerve growth factor (NGF) antibody from the Dutch antibody company PanGenetics. The deal, which is expected to close by the end of this year, also allows for a further $20 million in future milestone payments to PanGenetics.
You may also be interested in...
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.